Vivani Medical (VANI) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
The 2025 Annual Meeting will be held virtually on June 24, 2025, with a record date of April 25, 2025.
Stockholders will vote on the election of six directors, ratification of the independent auditor, and a non-binding advisory vote on executive compensation.
Proxy materials are primarily distributed via Internet access, with paper copies available upon request.
The Board recommends voting FOR all proposals.
Voting matters and shareholder proposals
Proposal 1: Elect six directors to serve until the 2026 annual meeting.
Proposal 2: Ratify BPM LLP as independent registered public accounting firm for 2025.
Proposal 3: Approve, on a non-binding advisory basis, the compensation of named executive officers.
Stockholders may submit proposals for the 2026 meeting by December 30, 2025.
Board of directors and corporate governance
The Board consists of six members, with a majority deemed independent under Nasdaq rules.
Three standing committees: Audit, Compensation, and Nominating and Corporate Governance, all composed of independent directors.
Board diversity is considered, with one female director and a range of professional backgrounds.
Directors attended at least 75% of meetings in 2024.
Insider Trading Policy prohibits short sales, hedging, and pledging of company securities.
Latest events from Vivani Medical
- Long-acting GLP-1 implants promise improved adherence and outcomes in obesity care.VANI
Corporate presentation26 Mar 2026 - Advanced semaglutide implant program and secured funding to support operations into mid-2027.VANI
Q4 202526 Mar 2026 - A once or twice-yearly GLP-1 implant targets adherence and access gaps in chronic disease care.VANI
2025 ThinkEquity Conference3 Feb 2026 - Long-acting implant technology targets improved adherence and outcomes in obesity and diabetes.VANI
H.C. Wainwright 26th Annual Global Investment Conference 202420 Jan 2026 - Long-acting GLP-1 implant targets improved adherence, with Phase I data expected by mid-2025.VANI
Maxim Group’s 2024 Healthcare Virtual Summit19 Jan 2026 - First-in-human trial of a six-month GLP-1 implant underway, with results expected mid-year.VANI
Emerging Growth Virtual Conference 7810 Jan 2026 - Proprietary drug implants show promise for obesity and diabetes, with key data expected mid-year.VANI
Emerging Growth Virtual Conference19 Dec 2025 - Semaglutide implant targets long-term adherence and tolerability in obesity care, with trials imminent.VANI
Emerging Growth Conference 202517 Dec 2025 - Shareholders will vote on directors, auditor ratification, and executive pay, with board support for all.VANI
Proxy Filing2 Dec 2025